RxDoctor Payments Data

Roland Goode, MD

Urology · Reno, NVNPI 1972765428

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Boston Scientific at 35.9% of the total. Reporting peaked in 2021 at $327 and has fallen 89.0% since, to $36 in 2025. That places this record below the midpoint for urology clinicians in NV, where the typical reported total is $2,990.

$873in general payments, 2019–2025

Across 43 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$313
  • AbbVie$261
  • Endo Pharmaceuticals Inc.$56
  • Procept Biorobotics Corporation$53
  • Astellas Pharma US Inc$52
  • Urogen Pharma, Inc.$48
  • plus $90 from 5 others

What the payments were for

  • Food & beverage$81593%
  • Education$577%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$873 in reported general payments places this provider in the 20th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$314,422
Medicare patients
768
Services billed
4,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiaflexCollagenase Clostridium Hist.26$345,457
MyrbetriqMirabegron144$127,236
GemtesaVibegron18$18,993
Fesoterodine Fumarate ErFesoterodine Fumarate90$9,536
Tamsulosin Hcl442$9,496
Alfuzosin Hcl ErAlfuzosin Hcl284$7,402
XyostedTestosterone Enanthate12$7,157
Mirabegron ErMirabegron11$6,436
Testosterone35$4,744
Tadalafil68$4,211
Potassium Citrate ErPotassium Citrate24$2,599
Methenamine Hippurate20$2,360
Finasteride145$2,106
Oxybutynin Chloride ErOxybutynin Chloride74$1,837
Testosterone Cypionate29$1,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Endo Pharmaceuticals Inc.Xiaflex$56$345,45726 claims
Astellas Pharma US IncMyrbetriq$52$127,236144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 63 urology providers in Nevada.

Other urology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →